Breaking News Instant updates and real-time market news.

SPPI

Spectrum

$10.97

1.07 (10.81%)

07:02
09/28/17
09/28
07:02
09/28/17
07:02

Spectrum highlights poziotinib data in lung cancer to be presented at IASLC

Spectrum Pharmaceuticals announced the release of an abstract from a clinical study evaluating poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer by scientists from The University of Texas MD Anderson Cancer Center, the sponsor of the trial. This abstract contains limited data as of the submission deadline of June 21, 2017. Additional data from their clinical experience and the ongoing Phase 2 study will be released in an oral presentation at the 18th International Association for the Study of Lung Cancer World Conference on Lung Cancer in Yokohama, Japan, October 15-18, 2017. "Approximately 10% of EGFR mutant NSCLCs have an insertion/mutation in exon 20 of EGFR resulting in primary resistance to currently available tyrosine kinase inhibitors. We previously reported that the structural features of poziotinib could potentially enable it to circumvent the steric hindrance induced by exon 20 mutations. Here we further characterize the preclinical activity of poziotinib and report on initial clinical activity of poziotinib in patients EGFR exon 20 mutations from an ongoing phase II study. To date, 8 platinum-refractory patients with EGFR exon 20 insertion mutation metastatic NSCLC have been enrolled in the clinical trial and treated with poziotinib at a dose of 16 mg PO daily. Two patients have reached the first interval-imaging time point. Both patients exhibited dramatic partial response, with one patient reporting improvement in dyspnea and cough at one week of therapy. In this early stage of the study, one case of grade 3 paronchycia was observed. One additional platinum- and erlotinib-refractory patient with EGFR exon 20 insertion was treated with poziotinib on compassionate basis. The patient achieved partial response after three weeks of treatment. Conclusion: Poziotinib has selective activity against EGFR exon 20 mutations and potent activity in cell lines, PDX, and GEM models. Three platinum-refractory patients with EGFR exon 20 mutations have been treated thus far and are evaluable for response; all three had partial responses at the time of the initial scan. Updated data from the ongoing phase 2 clinical trial of poziotinib will be presented at the meeting."

SPPI Spectrum
$10.97

1.07 (10.81%)

02/10/17
JEFF
02/10/17
UPGRADE
Target $7.5
JEFF
Buy
Spectrum assumed with a Buy from Hold at Jefferies
Jefferies analyst Matthew Andrews upgraded Spectrum Pharmaceuticals to Buy after assuming coverage of the name. The stock is undervalued based on Rolontis' long-term promise in chemotherapy-induced neutropenia, Andrews tells investors in a research note. The analyst sees 50%-plus share upside on expectations that Rolontis is lower risk and should gain meaningful market share from Neulasta. He has a $7.50 price target for Spectrum.
08/16/17
HCWC
08/16/17
INITIATION
Target $14
HCWC
Buy
Spectrum assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Edward White assumed coverage of Spectrum Pharmaceuticals with a Buy rating and $14 price target. The analyst has confidence in the company's pipeline, which he believe holds two potential blockbusters in Rolontis and poziotinib.
09/25/17
JEFF
09/25/17
NO CHANGE
Target $13
JEFF
Buy
Spectrum price target raised to $13 from $9 at Jefferies
Jefferies analyst Matthew Andrews raised his price target for Spectrum Pharmaceuticals to $13 ahead of initial Phase II data at the World Conference on Lung Cancer. The analyst views poziotinib as an "under the radar" non-small cell lung cancer drug. He sees exon 20 as a potential $1B U.S. market for poziotinib. If the overall response rate in Phase II around 25%, the drug could qualify for FDA Breakthrough Designation and reach the market by 2020, which could drive "meaningful" upside to Spectrum shares, Andrews tells investors in a research note. He keeps a Buy rating on the name.
09/28/17
JEFF
09/28/17
NO CHANGE
Target $13
JEFF
Buy
Spectrum data early but encouraging, says Jefferies
Jefferies analyst Matthew Andrews believes abstracts for the World Conference on Lung Cancer show "very encouraging efficacy" for Spectrum Pharmaceuticals' poziotinib. In a research note titled "Poziotinib WCLC Data Don't Disappoint...Can't Beat 100% ORR," Andrews says he continues to see "meaningful upside" in Spectrum shares through the end of 2017. The two partial responses complement the PR observed in a HER2 exon 20 patient in a compassionate use study, the analyst notes. He keeps a Buy rating on Spectrum with a $13 price target. The stock in premarket trading is up 3.65% to $11.37.

TODAY'S FREE FLY STORIES

TEST

DEF Company

22:17
02/19/18
02/19
22:17
02/19/18
22:17
Recommendations
DEF Company analyst commentary  

Technical testing 2217

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.75

-0.58 (-1.91%)

22:15
02/19/18
02/19
22:15
02/19/18
22:15
Downgrade
Teck Resources rating change  »

Teck Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.75

-0.58 (-1.91%)

22:14
02/19/18
02/19
22:14
02/19/18
22:14
Downgrade
Teck Resources rating change  »

Teck Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.75

-0.58 (-1.91%)

22:14
02/19/18
02/19
22:14
02/19/18
22:14
Downgrade
Teck Resources rating change  »

Teck Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.75

-0.58 (-1.91%)

22:14
02/19/18
02/19
22:14
02/19/18
22:14
Downgrade
Teck Resources rating change  »

Teck Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMG

Chipotle

$305.63

18.98 (6.62%)

22:13
02/19/18
02/19
22:13
02/19/18
22:13
Upgrade
Chipotle rating change  »

Chipotle upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMG

Chipotle

$305.63

18.98 (6.62%)

22:12
02/19/18
02/19
22:12
02/19/18
22:12
Upgrade
Chipotle rating change  »

Chipotle upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

H

Hyatt

$79.73

-0.02 (-0.03%)

22:09
02/19/18
02/19
22:09
02/19/18
22:09
Upgrade
Hyatt rating change  »

Hyatt upgraded to In Line…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

H

Hyatt

$79.73

-0.02 (-0.03%)

22:09
02/19/18
02/19
22:09
02/19/18
22:09
Upgrade
Hyatt rating change  »

Hyatt upgraded to In Line…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

FLS

Flowserve

$44.05

1.18 (2.75%)

22:07
02/19/18
02/19
22:07
02/19/18
22:07
Upgrade
Flowserve rating change  »

Flowserve upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

FLS

Flowserve

$44.05

1.18 (2.75%)

22:07
02/19/18
02/19
22:07
02/19/18
22:07
Upgrade
Flowserve rating change  »

Flowserve upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

TEST

DEF Company

22:01
02/19/18
02/19
22:01
02/19/18
22:01
Recommendations
DEF Company analyst commentary  

Technical testing 2201

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEST

DEF Company

21:13
02/19/18
02/19
21:13
02/19/18
21:13
Recommendations
DEF Company analyst commentary  

Technical Testing 2113

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEST

DEF Company

20:49
02/19/18
02/19
20:49
02/19/18
20:49
Recommendations
DEF Company analyst commentary  

Technical testing 2049

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEST

DEF Company

20:41
02/19/18
02/19
20:41
02/19/18
20:41
Hot Stocks
technical testing 

technical testing

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANAB

AnaptysBio

$126.45

6.59 (5.50%)

, SNY

Sanofi

$39.91

0.19 (0.48%)

20:02
02/19/18
02/19
20:02
02/19/18
20:02
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

ANAB

AnaptysBio

$126.45

6.59 (5.50%)

SNY

Sanofi

$39.91

0.19 (0.48%)

REGN

Regeneron

$332.15

-1.03 (-0.31%)

SNAP

Snap

$20.42

0.67 (3.39%)

GE

General Electric

$15.05

0.2 (1.35%)

DIS

Disney

$106.53

1.35 (1.28%)

GOOG

Alphabet

$1,094.80

5.28 (0.48%)

GOOGL

Alphabet Class A

$1,095.50

4.14 (0.38%)

LRCX

Lam Research

$187.91

2.2 (1.18%)

C

Citi

$76.82

-0.26 (-0.34%)

CMI

Cummins

$165.60

0.58 (0.35%)

JPM

JPMorgan

$114.68

-0.83 (-0.72%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

WMT

Walmart

$104.78

1.55 (1.50%)

PFE

Pfizer

$36.26

0.55 (1.54%)

CSCO

Cisco

$44.33

0.25 (0.57%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

PEP

PepsiCo

$111.06

0.09 (0.08%)

MMM

3M

$236.67

1.8 (0.77%)

BMY

Bristol-Myers

$68.96

-0.02 (-0.03%)

UTX

United Technologies

$129.26

-0.74 (-0.57%)

TXN

Texas Instruments

$104.47

-0.1 (-0.10%)

ABT

Abbott

$60.17

0.67 (1.13%)

HOV

Hovnanian

$2.24

0.12 (5.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

  • 21

    Feb

  • 23

    Feb

  • 23

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 05

    Mar

  • 06

    Mar

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 13

    Mar

  • 18

    Mar

  • 25

    Mar

  • 28

    Mar

  • 29

    Mar

  • 29

    Mar

  • 04

    Apr

  • 13

    Apr

  • 23

    Apr

  • 02

    May

  • 03

    May

  • 30

    May

  • 14

    Jul

  • 12

    Oct

CUB

Cubic

19:34
02/19/18
02/19
19:34
02/19/18
19:34
Hot Stocks
Cubic names president, CEO Bradley Feldmann as Chairman of the Board »

Cubic Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 06

    Mar

  • 07

    Mar

  • 08

    Mar

  • 14

    Jun

HCLP

Hi-Crush Partners

$12.40

0.25 (2.06%)

19:10
02/19/18
02/19
19:10
02/19/18
19:10
Earnings
Breaking Earnings news story on Hi-Crush Partners »

Hi-Crush Partners expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 28

    Feb

HCLP

Hi-Crush Partners

$12.40

0.25 (2.06%)

19:08
02/19/18
02/19
19:08
02/19/18
19:08
Earnings
Hi-Crush Partners reports Q4 diluted EPS 47c, consensus 51c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 28

    Feb

FSS

Federal Signal

$19.40

0.15 (0.78%)

19:04
02/19/18
02/19
19:04
02/19/18
19:04
Hot Stocks
Federal Signal declares dividend of 7c per share »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCE

BCE

$44.49

-0.02 (-0.04%)

19:03
02/19/18
02/19
19:03
02/19/18
19:03
Hot Stocks
BCE reports results of Series AC, AD Preferred Share conversions »

BCE announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

PRGX

PRGX Global

$7.95

0.35 (4.61%)

18:38
02/19/18
02/19
18:38
02/19/18
18:38
Hot Stocks
PRGX Global announces appointment of new Chief Product Officer »

PRGX Global announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

CRMT

America's Car-Mart

$46.25

0.6 (1.31%)

18:37
02/19/18
02/19
18:37
02/19/18
18:37
Earnings
America's Car-Mart reports Q3 revenue $$147M, consensus $136.24M »

Reports Q3 $1.82 per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

TAX

Liberty Tax

18:30
02/19/18
02/19
18:30
02/19/18
18:30
Hot Stocks
Liberty Tax Service taps Nicole Ossenfort to be CEO »

Liberty Tax, the parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TAX

Liberty Tax

18:29
02/19/18
02/19
18:29
02/19/18
18:29
Hot Stocks
Shaun York to be Chief Operating Officer for Liberty Tax Service »

Liberty Tax, the parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.